Norovirus Group-2
Protein is 95% pure as determined by 10% PAGE (coomassie staining).
Description
The Recombinant Norovirus Group-2 Capsid, E.Coli derived, is a positive sense RNA virus with 7.5kb nucleotides, encoding a major structural protein VP1 with 58~60kDa. The Recombinant Norovirus has two groups, group 1 and group 2. Group 2 recombinant capsid was derived from the full length capsid 53 to 548Aa.
Product Specs
Product Science Overview
Noroviruses are a leading cause of acute nonbacterial gastroenteritis worldwide, affecting people of all ages. These viruses belong to the Caliciviridae family and are classified into several genogroups, with Genogroup II (GII) being one of the most prevalent and clinically significant. The capsid protein of noroviruses, particularly the major capsid protein VP1, plays a crucial role in the virus’s ability to infect host cells and elicit immune responses.
The norovirus capsid is primarily composed of the VP1 protein, which forms virus-like particles (VLPs) when expressed recombinantly. The VP1 protein is divided into two main domains: the shell (S) domain and the protruding (P) domain. The S domain forms the structural core of the capsid, while the P domain extends outward and is involved in receptor binding and immune recognition .
Recombinant expression systems have been developed to produce norovirus capsid proteins for research and vaccine development. These systems often use eukaryotic or prokaryotic hosts to express the VP1 protein, which then self-assembles into VLPs. These VLPs are morphologically and antigenically similar to native norovirus particles but lack the viral RNA, making them non-infectious .
- Vaccine Development: Recombinant norovirus VLPs are being explored as potential vaccine candidates. They can elicit strong immune responses and have shown promise in preclinical and clinical trials.
- Diagnostic Tools: Recombinant capsid proteins are used in serological assays to detect norovirus-specific antibodies in human sera, aiding in the diagnosis of norovirus infections.
- Research: These proteins are invaluable in studying the interaction between noroviruses and host receptors, as well as in understanding the immune response to norovirus infections .
Despite the progress made in the recombinant expression of norovirus capsid proteins, several challenges remain. One major challenge is the genetic diversity of noroviruses, which complicates the development of broadly protective vaccines. Additionally, the lack of a robust cell culture system for human noroviruses hinders the study of viral replication and pathogenesis .
Future research is focused on overcoming these challenges by developing more efficient expression systems, exploring novel adjuvants to enhance vaccine efficacy, and identifying conserved epitopes that can be targeted by broadly neutralizing antibodies .
